Myriad Genetics (MYGN) Tops Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.68 +0.35%
Revenue Growth %: -3.3%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
FCNCA, PBCO, ARBV, More
Revenue Growth %: -3.3%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
FCNCA, PBCO, ARBV, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.30, $0.04 better than the analyst estimate of $0.26. Revenue for the quarter came in at $200.5 million versus the consensus estimate of $193.74 million.
GUIDANCE:
Myriad Genetics sees FY2018 EPS of $1.00-$1.05. Myriad Genetics sees FY2018 revenue of $750-770 million, versus the consensus of $1.01 and $764.72 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe upgrades AT&T to Outperform as improving fundamentals outweigh Starlink risk
- Acme United (ACU) Tops Q2 EPS by 41c
- Old Second Bancorp (OSBC) Misses Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
